Lupin receives US FDA Establishment Inspection Report for Somerset facility

Lupin has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its manufacturing facility in Somerset, New Jersey. The report follows an inspection conducted from 27 January to 31 January 2025.

Nilesh Gupta, Managing Director of Lupin, stated, “We are very pleased to have received the EIR for our Somerset facility. This milestone underscores our commitment to upholding the highest standards of quality and compliance, solidifying our position as a leading pharmaceutical manufacturer.”

Related Posts

  • Pharma
  • May 10, 2025
  • 105 views
Pharma sector continues to thrive, driven by price-led expansion

The Indian pharmaceutical market continued rising in April 2025, achieving a strong annual growth of 7.8%, with total sales reaching a remarkable Rs 19,711 crore. According to a report by…

  • Pharma
  • May 10, 2025
  • 107 views
TPG to acquire 35% stake in SCHOTT Poonawalla from SII

Mumbai:  SCHOTT Pharma has announced that TPG, a global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in its joint venture SCHOTT Poonawalla…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Pharma sector continues to thrive, driven by price-led expansion

Pharma sector continues to thrive, driven by price-led expansion

TPG to acquire 35% stake in SCHOTT Poonawalla from SII

TPG to acquire 35% stake in SCHOTT Poonawalla from SII

Indian pharma industry showed impressive growth in April 2025, by price led expansion: Report

Indian pharma industry showed impressive growth in April 2025, by price led expansion: Report

Diabetes drug shows promise for treating prostate cancer

Diabetes drug shows promise for treating prostate cancer